tiprankstipranks
Advertisement
Advertisement
Charles Zhu Doubles Immunome Price Target to $40 on ADC Pipeline Progress and Favorable Risk‑Reward Profile
PremiumRatingsCharles Zhu Doubles Immunome Price Target to $40 on ADC Pipeline Progress and Favorable Risk‑Reward Profile
28d ago
Immunome announces first patient dosed in Phase 1 trial of IM-1617
Premium
The Fly
Immunome announces first patient dosed in Phase 1 trial of IM-1617
28d ago
Immunome Reaffirmed at Buy as Varegacestat Data Underscore Competitive Edge; $40 Price Target Maintained
Premium
Ratings
Immunome Reaffirmed at Buy as Varegacestat Data Underscore Competitive Edge; $40 Price Target Maintained
1M ago
Immunome price target lowered to $33 from $37 at Leerink
PremiumThe FlyImmunome price target lowered to $33 from $37 at Leerink
2M ago
Immunome Price Target Maintained at $35 as Analyst Sees Best-in-Class Potential for Varegacestat in Desmoid Tumors
Premium
Ratings
Immunome Price Target Maintained at $35 as Analyst Sees Best-in-Class Potential for Varegacestat in Desmoid Tumors
2M ago
Analyst Reiterates Buy on Immunome, Maintains $40 Price Target on Varegacestat Progress and Pipeline Upside
Premium
Ratings
Analyst Reiterates Buy on Immunome, Maintains $40 Price Target on Varegacestat Progress and Pipeline Upside
2M ago
Immunome price target lowered to $30 from $32 at Lake Street
PremiumThe FlyImmunome price target lowered to $30 from $32 at Lake Street
4M ago
Immunome price target raised to $36 from $33 at Craig-Hallum
Premium
The Fly
Immunome price target raised to $36 from $33 at Craig-Hallum
4M ago
Immunome price target lowered to $30 from $33 at Stephens
Premium
The Fly
Immunome price target lowered to $30 from $33 at Stephens
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100